“A Quick Guide to Clinical Trials” Book Review
A brief review of “A Quick Guide to Clinical Trials,” edited by Dr. Madhu Davies and Dr. Faiz Kermain.
May 14, 2008-“A Quick Guide to Clinical Trials,” edited by Dr. Madhu Davies and Dr. Faiz Kermain, and offered by BioPlan Associates, truly lives up to its title. While it could serve as a textbook for a primer class on the clinical trials industry, the quick read would be suitable for anyone wishing to learn more about clinical trials-including people outside or inside the industry. If you are in data management, for example, and want to learn more about ethics in clinical research-or vise versa-this would be a useful resource. The book consists of 14 chapters dedicated to a different segment of the clinical trials process, each written by an industry expert. The information is up-to-date and offers personal, yet professional, insights into the current issues applicable to that segment.
For more information or to purchase, contact: www.bioplanassociates.com/quickGuides.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
